We found that FAS mRNA expression was correlated with better survival in breast cancer, gastric cancer and lung cancer, but it was associated with a worse prognosis in pancreatic cancer and AML; no relationship was found with kidney cancer, head and neck cancer, hepatic cancer, glioblastoma, colorectal cancer or ovarian cancer. This evidence concerns the gene FAS and kidney cancer.